Loading...
XSTO
ICO
Market cap3mUSD
May 09, Last price  
1.45SEK
1D
0.69%
1Q
-68.06%
IPO
-95.83%
Name

Iconovo AB

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
10.49
EPS
—
Div Yield, %
—
Shrs. gr., 5y
20.33%
Rev. gr., 5y
-24.22%
Revenues
3m
-58.55%
149,69714,377,00020,072,00011,907,82211,737,07917,791,60115,409,13317,116,1657,078,2882,934,000
Net income
-41m
L-10.36%
-897,3752,461,0001,453,000-4,294,552-11,005,976-17,133,888-26,160,589-50,309,657-45,893,831-41,140,000
CFO
-25m
L-36.43%
6,019,000-3,817,000-1,016,427-12,082,273-15,959,565-11,012,842-43,703,916-38,602,795-24,539,000
Earnings
Jul 10, 2025

Profile

Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler, as well as provides customized inhalation solutions. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius AB (publ) to develop inhalation product to treat COPD. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.
URL
https://www.iconovo.se/
IPO date
Apr 06, 2018
Employees
31
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,934
-58.55%
7,078
-58.65%
17,116
11.08%
Cost of revenue
(16,199)
(10,499)
4,805
Unusual Expense (Income)
NOPBT
19,133
17,578
12,311
NOPBT Margin
652.11%
248.33%
71.93%
Operating Taxes
2,147
Tax Rate
17.44%
NOPAT
19,133
17,578
10,164
Net income
(41,140)
-10.36%
(45,894)
-8.78%
(50,310)
92.31%
Dividends
Dividend yield
Proceeds from repurchase of equity
61,954
74,167
BB yield
-87.29%
-61.38%
Debt
Debt current
3,474
2,818
2,332
Long-term debt
12,334
12,632
17,730
Deferred revenue
Other long-term liabilities
1,000
Net debt
(13,949)
(3,030)
6,615
Cash flow
Cash from operating activities
(24,539)
(38,603)
(43,704)
CAPEX
(21,902)
(712)
(36,951)
Cash from investing activities
(21,902)
(22,911)
(36,951)
Cash from financing activities
52,651
66,547
(936)
FCF
25,589
16,327
(4,954)
Balance
Cash
29,757
18,480
13,446
Long term investments
Excess cash
29,610
18,126
12,591
Stockholders' equity
(189,082)
(148,889)
(103,345)
Invested Capital
326,198
270,140
201,198
ROIC
6.42%
7.46%
5.17%
ROCE
13.95%
14.50%
12.58%
EV
Common stock shares outstanding
17,145
10,462
8,848
Price
4.14
-64.16%
11.55
-76.43%
49.00
-36.36%
Market cap
70,979
-41.26%
120,833
-72.13%
433,528
-32.26%
EV
57,030
117,802
440,143
EBITDA
19,133
35,509
19,252
EV/EBITDA
2.98
3.32
22.86
Interest
550
512
302
Interest/NOPBT
2.87%
2.91%
2.46%